- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Dr Jawad Saleh: There Are Many Risk Factors for PONV
There are many risk factors for developing postoperative nausea and vomiting (PONV), but a simplified risk score can help with assessing those risk factors, said Jawad N. Saleh, PharmD, BSPharm, BCCCP, BCPS, clinical manager of pharmacy services, Hospital for Special Surgery.
There are many risk factors for developing postoperative nausea and vomiting (PONV), but a simplified risk score can help with assessing those risk factors, said Jawad N. Saleh, PharmD, BSPharm, BCCCP, BCPS, clinical manager of pharmacy services, Hospital for Special Surgery.
Transcript
What are some of the most common risk factors for postoperative nausea and vomiting? How should these risks be assessed to understand treatment?
The risk factors are vast. If you look into it, there's so many risk factors. But based on the Apfel study, if you look at the Apfel simplified risk score—which I actually encourage and it's also encouraged in the consensus guidelines that were recently published—if you're female, that's a risk factor. If you are a nonsmoker, that's a risk factor. If you have a history of PONV or motion sickness, that's a risk factor. And if you're getting opioids, that's a risk factor.
So those are the 4 Apfel simplified risk factors and, honestly, it puts a large number of people in more of a moderate- or high-risk state of PONV. Keeping that in mind, the average PONV rate is 30%; it’s 80% for high-risk patients. At Hospital for Special Surgery, we've been doing an amazing job—we're well below that number. And hopefully, we continue to reduce that number.
NGS-Based Test Accurately Detects Post–Allo-HSCT Relapse in AML, MDS
February 21st 2025The next-generation sequencing (NGS)–based AlloHeme test accurately predicted relapse following allogeneic hematopoietic stem cell transplantation (allo-HSCT) in acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS).
Read More
Prostate Cancer Studies Show Why Personalized Treatment, Trial Diversity Matter, Dorff Says
February 21st 2025Tanya B. Dorff, MD, medical oncologist and professor in City of Hope’s Department of Medical Oncology & Therapeutics Research, was a discussant for the TALAPRO-2 and STOPCAP trials at the opening session of ASCO GU.
Read More
Politics vs Science: The Future of US Public Health
February 4th 2025On this episode of Managed Care Cast, we speak with Perry N. Halkitis, PhD, MS, MPH, dean of the Rutgers School of Public Health, on the public health implications of the US withdrawal from the World Health Organization and the role of public health leaders in advocating for science and health.
Listen
NSCLC Advancements Offer Hope, but Disparities Persist
February 20th 2025Ioana Bonta, MD, Georgia Cancer Specialists, discusses the evolving state of non-small cell lung cancer (NSCLC) treatments, their impact on patient outcomes, and the need to address ongoing disparities in these populations.
Read More
Abortion in 2025: Access, Fertility, and Infant Mortality Updates
February 20th 2025While Republican state-led efforts aim to increase restrictions to abortion care and access to mifepristone and misoprostol in 2025, JAMA authors join the conversation with their published research and commentary.
Read More
